K
Kimia Kamelian
Researcher at University of British Columbia
Publications - 8
Citations - 327
Kimia Kamelian is an academic researcher from University of British Columbia. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 3, co-authored 5 publications receiving 144 citations. Previous affiliations of Kimia Kamelian include Center for Excellence in Education.
Papers
More filters
Posted ContentDOI
Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore
John R. Tyson,Phillip James,David Stoddart,Natalie Sparks,Arthur Wickenhagen,Grant Hall,Ji Hyun Choi,Hope R. Lapointe,Kimia Kamelian,Andrew D. Smith,Natalie Prystajecky,Ian Goodfellow,Sam J. Wilson,Richard Harrigan,Terrance P. Snutch,Nicholas J. Loman,Joshua Quick +16 more
TL;DR: An updated primer scheme with 22 additional primers to improve genome coverage and cost savings which bring the reagent cost down to £10 per sample making it practical for individual labs to sequence thousands of SARS-CoV-2 genomes to support national and international genomic epidemiology efforts.
Journal ArticleDOI
Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013
Suzanne M. McCluskey,Guinevere Q. Lee,Kimia Kamelian,Kimia Kamelian,Annet Kembabazi,Nicholas Musinguzi,Mwebesa Bwana,Conrad Muzoora,Jessica E. Haberer,Peter W. Hunt,Jeffrey N. Martin,Yap Boum,David R. Bangsberg,P. Richard Harrigan,Mark J. Siedner,Mark J. Siedner +15 more
TL;DR: Impact of PDR on clinical outcomes in rural Uganda and implications of this trend, particularly to prevention of mother‐to‐child transmission programs in the region, require attention due to delayed viral suppression among those with PDR.
Journal ArticleDOI
Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis
Kimia Kamelian,Katherine J. Lepik,Katherine J. Lepik,William Chau,Benita Yip,Wendy Zhang,Viviane D. Lima,Marjorie Robbins,Conan K. Woods,Andrea D. Olmstead,Jeffrey B. Joy,Rolando Barrios,P. Richard Harrigan +12 more
TL;DR: The prevalence of INSTI resistance remains low compared with PI and RT resistance in ART-treated populations but is expanding with increased INSTI use.
Journal ArticleDOI
Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
Suzanne M. McCluskey,Kimia Kamelian,Nicholas Musinguzi,Simone H. Kigozi,Yap Boum,Mwebesa Bwana,Conrad Muzoora,Zabrina L. Brumme,Zabrina L. Brumme,Mary Carrington,Jonathan M. Carlson,Brian T. Foley,Peter W. Hunt,Jeffrey N. Martin,David R. Bangsberg,P. Richard Harrigan,Mark J. Siedner,Mark J. Siedner,Jessica E. Haberer,Guinevere Q. Lee,Guinevere Q. Lee,Guinevere Q. Lee +21 more
TL;DR: In this paper, the authors report prevalence of pre-treatment integrase polymorphisms associated with resistance to INSTIs in an ART-naive cohort with diverse HIV-1 subtypes.
Journal ArticleDOI
Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population‐based cohort study in British Columbia, Canada
Shannon L. Russell,B. Klaver,Sean Harrigan,Kimia Kamelian,John R. Tyson,L. P. Hoang,Marsha L. Taylor,Beate Sander,Sharmistha Mishra,Natalie Prystajecky,Naveed Z. Janjua,James E. A. Zlosnik,Hind Sbihi +12 more
TL;DR: In this paper , the authors report a propensity matched severity analysis from residents of BC over the course of the Omicron wave, including 39,237 individuals infected with BA.1, BA.2, and BA.5 based on paired high-quality sequence data and linked to comprehensive clinical outcomes data between December 23, 2021 and August 31, 2022.